Industry
Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 9:13 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:32 pm
Portfolio Pulse from Vandana Singh
April 11, 2024 | 5:44 pm
Portfolio Pulse from Avi Kapoor
April 11, 2024 | 5:33 pm
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 2:13 pm
Portfolio Pulse from Avi Kapoor
April 11, 2024 | 2:01 pm
Portfolio Pulse from Vandana Singh
April 09, 2024 | 6:26 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 8:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.